Format

Send to

Choose Destination
Med Oncol. 2016 May;33(5):52. doi: 10.1007/s12032-016-0764-6. Epub 2016 Apr 18.

Risk of interactions between complementary and alternative medicine and medication for comorbidities in patients with melanoma.

Author information

1
Department of Dermatology, University Medical Center Mainz, Langenbeckstraße 1, 55131, Mainz, Germany.
2
Institute of Occupational Medicine, University Hospital, RWTH Aachen University, Pauwelsstraße 30, 52074, Aachen, Germany.
3
Department of Dermatology, University Medical Center Dresden, Fetscherstraße 74, 01307, Dresden, Germany.
4
Department of Dermatology, Wald Klinikum Gera, Str. des Friedens 122, 07548, Gera, Germany.
5
Department of Dermatology, University Medical Center Kiel, Arnold-Heller-Straße 3, 24105, Kiel, Germany.
6
Practice of Dermatology, Bonner Str. 207, 50968, Cologne, Germany.
7
Department of Dermatology, Klinikum Dortmund gGmbH, Beurhausstraße 40, 44137, Dortmund, Germany.
8
Practice of Dermatology, Sachsenwerkstr. 71, 01257, Dresden, Germany.
9
Department of Radio-Oncology, St. Franziskus Hospital Bielefeld, Kiskerstraße 26, 33615, Bielefeld, Germany.
10
Department of Radio-Oncology, Ruhr University Bochum, Universitätsstraße 150, 44801, Bochum, Germany.
11
Department of Gynecology and Obstetrics, Clinic Offenburg, Ebertplatz 12, 77654, Offenburg, Germany.
12
Clinic Herzoghoehe Bayreuth, Kulmbacherstraße 103, 95445, Bayreuth, Germany.
13
Department of Medical Biometrie, Epidemiology and Informatics, University Medical Center Mainz, Langenbeckstraße 1, 55131, Mainz, Germany.
14
Dr. Senckenberg Chronomedical Institute, J.W. Goethe University, Theodor-Stern-Kai 7, 60590, Frankfurt, Germany. huebner@med.uni-frankfurt.de.

Abstract

Complementary and alternative medicine (CAM) is used widely among cancer patients. Beside the risk of interaction with cancer therapies, interactions with treatment for comorbidities are an underestimated problem. The aim of this study was to assess prevalence of interactions between CAM and drugs for comorbidities from a large CAM usage survey on melanoma patients and to classify herb-drug interactions with regard to their potential to harm. Consecutive melanoma outpatients of seven skin cancer centers were asked to complete a standardized CAM questionnaire including questions to their CAM use and their taken medication for comorbidities and cancer. Each combination of conventional drugs and complementary substances was evaluated for their potential of interaction. 1089 questionnaires were eligible for evaluation. From these, 61.6% of patients reported taking drugs regularly from which 34.4% used biological-based CAM methods. Risk evaluation for interaction was possible for 180 CAM users who listed the names or substances they took for comorbidities. From those patients, we found 37.2% at risk of interaction of their co-consumption of conventional and complementary drugs. Almost all patients using Chinese herbs were at risk (88.6%). With a high rate of CAM usage at risk of interactions between CAM drugs and drugs taken for comorbidities, implementation of a regular assessment of CAM usage and drugs for comorbidities is mandatory in cancer care.

KEYWORDS:

Cancer; Comorbidities; Complementary and alternative medicine; Interactions; Melanoma

PMID:
27090799
DOI:
10.1007/s12032-016-0764-6
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center